Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This study is a multi-center, randomized, open-label and positive controlled Phase II
Clinical trial to assess the efficacy and safety of Ypeginterferon alfa-2b (with Ribavirin),
once a week, in 3 dose-groups respectively, for treatment of Chronic Hepatitis C patients,
with Pegasys 180mcg/week & Ribavirin as positive control. It is aimed to establish a dose
response and safety relationship sufficient to allow the subsequent design and conduct of
Phase III trials, and generate the PK data in hepatitis C patients to satisfy regulatory
requirements.